Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-20
2006-06-20
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07064138
ABSTRACT:
Methods for the prophylaxis, treatment, or management of irritable bowel syndrome using (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer are disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4598123 (1986-07-01), Cutter
patent: 4962115 (1990-10-01), Van Daele
patent: 5057427 (1991-10-01), Wald et al.
patent: 5057525 (1991-10-01), Van Daele
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5075290 (1991-12-01), Findley et al.
patent: 5077217 (1991-12-01), Matson et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5137896 (1992-08-01), Van Daele
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5356934 (1994-10-01), Robertson et al.
patent: 5407953 (1995-04-01), Morgan
patent: 5422374 (1995-06-01), Miyao et al.
patent: 5502067 (1996-03-01), Morgan
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5618828 (1997-04-01), Gray et al.
patent: 5629328 (1997-05-01), Gray et al.
patent: 5629329 (1997-05-01), Gray et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5663173 (1997-09-01), Jegham et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5712293 (1998-01-01), McCullough et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5739151 (1998-04-01), McCullough et al.
patent: 5877188 (1999-03-01), McCullough et al.
patent: 5877189 (1999-03-01), McCullough et al.
patent: 5955477 (1999-09-01), Gray et al.
patent: 5955478 (1999-09-01), Gray et al.
patent: 6048879 (2000-04-01), Rubin et al.
patent: 6066654 (2000-05-01), Gray et al.
patent: 6069154 (2000-05-01), Gray et al.
patent: 6114356 (2000-09-01), McCullough et al.
patent: 0 076 530 (1983-04-01), None
patent: 0 364 274 (1990-04-01), None
patent: 0 748 807 (1996-12-01), None
patent: WO 94/01111 (1994-01-01), None
patent: WO 94/01112 (1994-01-01), None
patent: WO 95/01803 (1995-01-01), None
patent: WO 96/40133 (1996-12-01), None
patent: WO 98/03173 (1998-01-01), None
patent: WO 99/02496 (1999-01-01), None
Medline An 91178215, Van Outryve M et al, J Clin Gastroenter, Feb. 1991, 13(1) 49-57, abstract.
Van Outryve et al, J Clin Gastroenterol, 1991, 13(1), 49-57.
Barnes, N.M. et al., “Identification of 5-HT3Recognition Sites In The Ferret Area Postrema,”J. Pharm. Pharmacol., 40:586-588 (1988).
Blecker, U. et al., “The Role of “Occult” Gastroesophageal Reflux in Chronic Pulmonary Disease in Children,”Acta Gastro-Enterologica Belgica, 58(5-6):348-352 (1995).
Burks, T.F.,Principles of Pharmacology, 1996, pp. 1093-1100.
Burstein, E.S. et al., “Structure-Function of Muscarinic Receptor Coupling to G Proteins,”J. Biol. Chem., 270:3141-3146 (1995).
Clarke, D. E. et al., “The 5-HT4Receptor: Naughty, But Nice,”Trends in Pharmacological Sciences, 10:385-386 (1989).
Costall B., et al., “Emesis Induced By Cisplain In The Ferret As A Model For The Detection Of Anti-Emetic Drugs,”Neuropharmacology, 26:1321-1326 (1987).
Craig & Clark, “5-Hydroxytryptamine and Cholinergic Mechanisms in Guinea-pig Ileum,”Brit. J. Pharmacol.96:247 (1989).
Crow,Opin. Invest. Drugs, 6(4), 427-436 (1997).
Decktor, DL et al., “Effect of Metoclopramide, Bethanechol and the Cholecystokinin Receptor Antagonist, L-364, 718, on Gastric Emptying in the Rat,”Eur. J. Pharmacol. 147:313-316 (1988).
Dumuis, A. et al., “The Gastrointestinal Prokinetic Benzamide Derivatives are agonists at the non-classical 5-HT receptor (5-HT4) Positively Coupled To Adenylate Cyclase In Neurons,”N.S. Arch Pharmacol., 340:403-410 (1989).
Ebert, W. R., “Soft Elastic Gelatin Capsules: A Unique Dosage Form,”Pharm. Tech., 1(5):44-50 (1977).
Faris, P.L. et al.,“Nociceptive, but not Tactile, Thresholds are Elevated in Bulimia Nervosa,”Biol. Psychiatry32:462-466 (1992).
Fernandez & Massingham, “Peripheral Receptor Populations Involved in the Regulation of Gastrointestinal Motility and the Pharmacological Actions of Meoclopramide-like Drugs,”Life Sci. 36:1-14 (1985).
Frazer, A et al., “Subtypes of Receptors for Serotonin,”Annual Rev. of Pharmacology and Toxicology30:307-348 (1990).
Gladziwa, U et al., “Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis,”Clinical Pharmacology50:6:673-681 (1991).
Jamali, F., “Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls,”Journal of Pharmaceutical Sciences, 78(9):695-715 (1989).
Krejs, GJ “Sérotonine intestinale, une cible thérapeutique,”Méd. Chir. Dig.22:7:415-416 (1993).
Lauwers, W et al., “Identification of a Biliary Metabolite of Cisapride,”Biomedical and Environmental Mass Spectrometry15:323-328 (1988).
Lavrijsen, K et al., “The Role of CYP3A4 in theIn-VitroMetabolism of Cisapride in Human Liver Microsomes andIn-VitroandIn-VivoInteractions of Cisapride with Co-Administered Drugs,”Dept. of Pharmacokinetics and Drug Metabolism, Janssen Research Foundation.
Messier, T. L., et al., “High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neutrophin Receptors in Living Mammalian Cells,”Pharmacol. Toxicol., 76(5):308-311 (1995).
Meuldermans, W. et al., “Excretion and Biotransformation of Cisapride In Dogs and Humans After Oral Administration,”Drug Metab. Dispos., 16(3): 403-409 (1988).
Meuldermans, W. et al.,“Excretion and Biotransformatin of Cisapride in Rats After Oral Administration,”Drug Metab. Dispos., 16(3):410-419(1988).
Milo, R “Non-Cholinergic, Non-antidopaminergic Treatment of Chronic Digestive Symptoms Suggestive Of A Motility Disorder: A Two-Step Pilot Evaluation of Cisapride,”Curr. Therapeutic Research36:5:1053-1062 (1984).
Nemeth, P.R., “Gastrointestinal motility stimulating drugs and 5-HT receptors or Myenteric Neurons,”Eur. J. Pharmacol., 166:387-391 (1989).
Noor, N. et al., XP002128489, “Effects of Cisapride on Symptoms and Postcibal Small-Bowel Motor Function in Patients with irritable Bowel Syndrome”,Scandianavian J. Gastroent., 33(6)605-611 (1998).
Porsius, AJ et al., “Farmacotoets 6A,”Farmacotherapie129:9:214-217 (1994).
Preechagoon, Y. et al., “Analysis of Cisapride in Neonatal Plasma Using High-Performance Liquid Chromatography with a Base-Stable Column and Fluorescence Detection”,J. Chromatography B: Biomedical Applications, 670(1):139-143 (1995).
Reyntjens, A et al., “Clinical Pharmacological Evidence For Cisapride's Lack of Antidopaminergic or Direct Cholinergic Properties,”Current Therapeutic Research36:5:1045-1052 (1984).
Rissanen et al.,J. Clin. Psychopharmacol., 18(1): 26-32 (1998).
Schapira, M. et al., “The Current Status of Gastric Prokinetic Drugs,”Acta Gastroenterolog. Belg., 53:446-457 (1990).
Schiavi, GB et al., “Identification of Serotonin 5-HT4Recognition Sites in the Porcine Caudate Nucleus by Radioligand Binding,”Neuropharmacology33:543-549 (1994).
Schuurkes, JAJ et al., “Motor-Stimulating Properties of Cisapride on Isolated Gastrointestinal Preparations of the Guinea Pig.”J. Pharmacol. Exp. Ther.234:775-783 (1985).
Shah, M., “Gastroesophageal Reflux—How to Mend it?”Indian J. Pediatr., 63:441-445 (1996).
Skinner S., “Gastric Ulcer Presenting as Gastroesophageal Reflux and Apnea in a Term Neonate,”Tex. Medic., 94(9):57-58 (1998).
Stacher, G et al., “Effects of Oral Cisapride on Interdigestive Jejunal Motor Activity, Psychomotor Function, and Side-Effect Profile in Healthy Man,”Digestive Diseases and Sciences32:11:1223-1230 (1987).
Van Peer, A. et al., “Clinical Pharmacokinetics of Cisapride,”Excerpta Medica, Current Clinical Practice Series, A.G. Johnson and G. Lux, Eds. Amst
Barberich Timothy J.
Rubin Paul D.
Cook Rebecca
Jones Day
Sepracor Inc.
LandOfFree
Methods for treating irritable bowel syndrome using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating irritable bowel syndrome using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating irritable bowel syndrome using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3654715